Regeneron Pharmaceuticals, Inc., founded in 1988 and headquartered in Tarrytown, New York, is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines for serious diseases. The company's key products include EYLEA, a treatment for eye diseases, and Dupixent, which targets various allergic conditions and asthma.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| REGN 1.75% 2030-09-15 USDRegeneron Pharmaceuticals, Inc. | United States | 2030-09-15 | 1.750 | 4.41 |
| REGN 2.80% 2050-09-15 USDRegeneron Pharmaceuticals, Inc. | United States | 2050-09-15 | 2.800 | 5.74 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Regeneron began issuing bonds in 2014 to support its growth initiatives and operational needs. Significant issuances include a $1 billion offering in 2021, which was used for general corporate purposes and to bolster R&D funding. As of October 2023, the company's bonds exhibit competitive yields compared to the industry average, reflecting strong investor confidence, while their recent focus on sustainability and strategic growth positions them favorably in the investment landscape.